AZTR Azitra Corporation: Koefisien utang jangka dawa marang modal

The development of Azitra, Inc. (AZTR) relies on the success of genetically modified bacteria trials, while financial stability requires strict cost monitoring. This price chart (separate_debt_long_eq) captures the 0.01 metric. FDA approvals and progress in developing the ATR-12 therapy are driving the growth of the business value. Azitra, Inc. (AZTR) has earned pioneer status in the field of microbiome epidermis restoration, gaining recognition among dermatologists.

This metric reflects the ratio of liabilities with a maturity of over one year to equity, reacting promptly to the restructuring of liabilities. The indicator determines the company's degree of dependence on external financing and debt service risks. For Azitra, Inc. (AZTR), this is critical during capital-intensive investments in its modified bacteria R&D platform. Outsourcing production allows for cost optimization, reducing the need for loans. The trend of the long-term debt structure ratio confirms the stability of the financial leverage.